Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Expert Opin Biol Ther. 2016 Aug 8;16(10):1303–1309. doi: 10.1080/14712598.2016.1217988

Table 3.

Comparison of phase III studies of sarilumab and tocilizumab in MTX-IRs: ACR response rates at 24 weeks

Placebo 150 mg 200 mg
Sarilumab
MOBILITY Study, part B42
Genovese et al.
ACR 20 33% 58% 66%
ACR 50 17% 37% 46%
ACR 70 7% 20% 25%
Placebo 4 mg/kg 8 mg/kg
Tocilizumab
OPTION Study29
Smolen et al.
ACR 20 26% 48% 59%
ACR 50 11% 32% 11%
ACR 70 2% 12% 22%
Placebo 4 mg/kg 8 mg/kg
Tocilizumab
LITHE Study28
Kremer et al.
ACR 20 27% 51% 56%
ACR 50 10% 25% 32%
ACR 70 2% 11% 13%